These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38236700)

  • 1. Number of buprenorphine induction attempts impacts maternal and neonatal outcomes: a multicenter cohort study.
    Kelly JC; Ayala NK; Holroyd L; Raghuraman N; Carter EB; Williams SA; Mills MM; Friedman H; Zhang F; Townsel C
    Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100998. PubMed ID: 38236700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study.
    Mullins N; Galvin SL; Ramage M; Gannon M; Lorenz K; Sager B; Coulson CC
    J Addict Med; 2020; 14(3):185-192. PubMed ID: 31567599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.
    Suarez EA; Huybrechts KF; Straub L; Hernández-Díaz S; Jones HE; Connery HS; Davis JM; Gray KJ; Lester B; Terplan M; Mogun H; Bateman BT
    N Engl J Med; 2022 Dec; 387(22):2033-2044. PubMed ID: 36449419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study.
    Wang S; Meador KJ; Pawasauskas J; Lewkowitz AK; Ward KE; Brothers TN; Hartzema A; Quilliam BJ; Wen X
    Drug Saf; 2023 Mar; 46(3):257-271. PubMed ID: 36642778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone.
    Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid Use Disorder and Perinatal Outcomes.
    Piske M; Homayra F; Min JE; Zhou H; Marchand C; Mead A; Ng J; Woolner M; Nosyk B
    Pediatrics; 2021 Oct; 148(4):. PubMed ID: 34479983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone.
    Straub L; Bateman BT; Hernández-Díaz S; Zhu Y; Suarez EA; Vine SM; Jones HE; Connery HS; Davis JM; Gray KJ; Lester B; Terplan M; Zakoul H; Mogun H; Huybrechts KF
    JAMA; 2024 Sep; 332(10):805-816. PubMed ID: 39133511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway.
    Nechanská B; Mravčík V; Skurtveit S; Lund IO; Gabrhelík R; Engeland A; Handal M
    Addiction; 2018 Jul; 113(7):1286-1294. PubMed ID: 29443414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder.
    Abdelwahab M; Petrich M; Wang H; Walker E; Cleary EM; Rood KM
    Am J Obstet Gynecol MFM; 2022 May; 4(3):100582. PubMed ID: 35123110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes associated with the use of medications for opioid use disorder during pregnancy.
    Krans EE; Kim JY; Chen Q; Rothenberger SD; James AE; Kelley D; Jarlenski MP
    Addiction; 2021 Dec; 116(12):3504-3514. PubMed ID: 34033170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy.
    O'Connor AB; Collett A; Alto WA; O'Brien LM
    J Midwifery Womens Health; 2013; 58(4):383-8. PubMed ID: 23931660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
    Debelak K; Morrone WR; O'Grady KE; Jones HE
    Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Care-by-parent model as a tool for reduction of neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero.
    Lawlor ML; Shook LA; McQuerry K; Srinivasan A; Johnson QB; Chavan NR; Critchfield AS
    J Matern Fetal Neonatal Med; 2020 Aug; 33(16):2718-2722. PubMed ID: 30563376
    [No Abstract]   [Full Text] [Related]  

  • 16. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.
    Zedler BK; Mann AL; Kim MM; Amick HR; Joyce AR; Murrelle EL; Jones HE
    Addiction; 2016 Dec; 111(12):2115-2128. PubMed ID: 27223595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes.
    Kanervo M; Tupola S; Nikkola E; Rantakari K; Kahila H
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():106-110. PubMed ID: 38608352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed villous maturation in term placentas exposed to opioid maintenance therapy: a retrospective cohort study.
    Serra AE; Lemon LS; Mokhtari NB; Parks WT; Catov JM; Venkataramanan R; Caritis SN
    Am J Obstet Gynecol; 2017 Apr; 216(4):418.e1-418.e5. PubMed ID: 28024988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal Outcomes after Medications for Opioid Use Disorder during Pregnancy in a State Women's Prison Facility, 2016-2019.
    Knittel AK; Swartzwelder RA; Zarnick S; Tsujimoto TM; Horne T; Lin FC; Edwards J; Amos E; Alexander J; Thorp J; Jones HE
    J Addict Med; 2023 Sep-Oct 01; 17(5):587-591. PubMed ID: 37788614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MATernaL and Infant NetworK to Understand Outcomes Associated with Treatment of Opioid Use Disorder During Pregnancy (MAT-LINK): Surveillance Opportunity.
    Tran EL; Kim SY; England LJ; Green C; Dang EP; Broussard CS; Fehrenbach N; Hudson A; Yowe-Conley T; Gilboa SM; Meaney-Delman D
    J Womens Health (Larchmt); 2020 Dec; 29(12):1491-1499. PubMed ID: 33227221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.